- Home
- TAK vs FANG Comparison
TAK vs FANG Comparison
Compare TAK & FANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAK | FANG |
|---|---|---|
| Founded | 1781 | 2007 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 45.9B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | TAK | FANG |
|---|---|---|
| Price | $15.89 | $140.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $187.61 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 01-29-2026 | 02-23-2026 |
| Dividend Yield | ★ 3.34% | 2.77% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.14 | ★ 14.37 |
| Revenue | ★ $29,846,840,032.00 | $14,626,000,000.00 |
| Revenue This Year | N/A | $43.88 |
| Revenue Next Year | $0.47 | N/A |
| P/E Ratio | $113.33 | ★ $10.06 |
| Revenue Growth | N/A | ★ 59.73 |
| 52 Week Low | $12.80 | $114.00 |
| 52 Week High | $15.97 | $180.91 |
Technical Indicators
Market Signals| Indicator | TAK | FANG |
|---|---|---|
| Relative Strength Index (RSI) | 77.29 | 35.86 |
| Support Level | $15.48 | $143.55 |
| Resistance Level | $15.78 | $154.58 |
| Average True Range (ATR) | 0.17 | 4.37 |
| MACD | 0.05 | -1.05 |
| Stochastic Oscillator | 94.15 | 7.15 |
Price Performance
Historical ComparisonAbout TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About FANG Diamondback Energy Inc.
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.